Mycosis fungoides screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Mycosis fungoides}} | ||
{{CMG}}; {{AE}} {{S.G.}} | {{CMG}}; {{AE}} {{S.G.}} | ||
==Overview== | ==Overview== |
Revision as of 19:03, 3 January 2019
Mycosis fungoides Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Mycosis fungoides screening On the Web |
American Roentgen Ray Society Images of Mycosis fungoides screening |
Risk calculators and risk factors for Mycosis fungoides screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
- According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for cutaneous T cell lymphoma.
Screening
- According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for cutaneous T cell lymphoma.